{"authors": [["Moulis", "Florence", "F", "Service de pharmacologie m\u00e9dicale et clinique, centre Midi-Pyr\u00e9n\u00e9es de pharmacovigilance, de pharmaco\u00e9pid\u00e9miologie et d'informations sur le m\u00e9dicament, facult\u00e9 de m\u00e9decine, CHU, 37, all\u00e9es Jules-Guesde, 31000 Toulouse, France. Electronic address: florence.moulis@univ-tlse3.fr."], ["Rousseau", "Vanessa", "V", "Service de pharmacologie m\u00e9dicale et clinique, centre Midi-Pyr\u00e9n\u00e9es de pharmacovigilance, de pharmaco\u00e9pid\u00e9miologie et d'informations sur le m\u00e9dicament, facult\u00e9 de m\u00e9decine, CHU, 37, all\u00e9es Jules-Guesde, 31000 Toulouse, France."], ["Abadie", "Delphine", "D", "Service de pharmacologie, centre r\u00e9gional de pharmacovigilance, groupe hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, 75651 Paris, France."], ["Masmoudi", "Kamel", "K", "Service de pharmacologie clinique, centre r\u00e9gional de pharmacovigilance d'Amiens, CHU, 80054 Amiens, France."], ["Micallef", "Jo\u00eblle", "J", "Centre r\u00e9gional de pharmacovigilance, pharmacovigilance Marseille-Provence-Corse, service de pharmacologie clinique et pharmacovigilance Assistance Publique - Hopitaux de Marseille, Aix-Marseille Universit\u00e9 et UMR 7289 - CNRS, 13005 Marseille, France."], ["Vigier", "Caroline", "C", "Service de pharmacologie clinique, centre r\u00e9gional de pharmacovigilance de Nice, CHU, 06003 Nice, France."], ["Pierre", "Sabrina", "S", "Service de pharmacologie clinique, centre r\u00e9gional de pharmacovigilance de Dijon, CHU, 21000 Dijon, France."], ["Dautriche", "Anne", "A", "Service de pharmacologie clinique, centre r\u00e9gional de pharmacovigilance de Dijon, CHU, 21000 Dijon, France."], ["Montastruc", "Fran\u00e7ois", "F", "Service de pharmacologie m\u00e9dicale et clinique, centre Midi-Pyr\u00e9n\u00e9es de pharmacovigilance, de pharmaco\u00e9pid\u00e9miologie et d'informations sur le m\u00e9dicament, facult\u00e9 de m\u00e9decine, CHU, 37, all\u00e9es Jules-Guesde, 31000 Toulouse, France; Laboratoire de pharmacologie m\u00e9dicale et clinique, facult\u00e9 de m\u00e9decine, 31000 Toulouse, France."], ["Montastruc", "Jean-Louis", "JL", "Service de pharmacologie m\u00e9dicale et clinique, centre Midi-Pyr\u00e9n\u00e9es de pharmacovigilance, de pharmaco\u00e9pid\u00e9miologie et d'informations sur le m\u00e9dicament, facult\u00e9 de m\u00e9decine, CHU, 37, all\u00e9es Jules-Guesde, 31000 Toulouse, France; Laboratoire de pharmacologie m\u00e9dicale et clinique, facult\u00e9 de m\u00e9decine, 31000 Toulouse, France."]], "date": "2017-06-29", "id": "28755832", "text": "Tramadol is an opioid and a serotonin reuptake inhibitor drug. It is approved for moderate to severe pain in adults. The aim of this study was to assess tramadol safety through a national pharmacovigilance study in France since dextropropoxyphen withdrawal in 2011.We described all serious adverse drug reactions (SADRs) reported with tramadol in adults in the French National PharmacoVigilance Database from August\u00a01st, 2011 to December\u00a031st, 2015.We identified 1512\u00a0SADRs during the study period. The most frequently reported SADRs were neurological (29.4%, including troubles of consciousness [13.2%] and seizures [6.7%]), psychiatric (22.8%, including confusions [14.6%] and hallucinations [7.3%]) and gastrointestinal (17.0%, mostly nausea and vomiting [9.6%]). Unexpected SADRs were also reported: hyponatremia, cholestatic hepatitis, serotonin syndrome.This study demonstrates new unexpected hepatic and metabolic SADRs. Tramadol alone can induce serotonin syndrome in overdose situations.", "doi": "10.1016/j.therap.2017.03.004", "title": "[Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011\u00a0and 2015].", "journal": ["Therapie", "Therapie"]}